Fresenius Medical Care Expands U.S. Evidence Base for High-Volume Hemodiafiltration Through BEACON-US Initiative
Fresenius Medical Care (FME), a global leader in products and services for people living with kidney disease, has announced the launch of BEACON-US, a comprehensive scientific research initiative designed to expand clinical and real-world evidence surrounding online-hemodiafiltration (HDF) for patients receiving dialysis in the United States.
The initiative, formally known as Benefits, Effectiveness, And Convective Outcomes in Nephrology – United States, comes as Fresenius Medical Care continues the rollout of high-volume hemodiafiltration (HVHDF) across the U.S. dialysis market. Through BEACON-US, the company aims to generate additional insights into the performance of the therapy in routine clinical practice, including how it is used across different patient populations and dialysis settings.
The initiative represents another step in Fresenius Medical Care’s broader efforts to strengthen evidence-based innovation in kidney care. As the prevalence and burden of kidney disease continue to increase, healthcare providers are seeking dialysis technologies that can improve treatment experiences while supporting clinical outcomes and efficient delivery of care.
Helen Giza, CEO of Fresenius Medical Care, said the company views evidence generation as a central component of its innovation strategy. According to Giza, high-volume hemodiafiltration could play an important role in changing the standard of kidney care in the United States and is a significant element of the company’s FME Reignite strategy, which focuses on accelerating growth, innovation and clinical value.
Giza also pointed to encouraging early observations from the BEACON-US initiative and the potential for the therapy to contribute to improved outcomes for people receiving dialysis.
Early U.S. Experience With High-Volume HDF Shows Encouraging Results
Fresenius Medical Care said early U.S. experience with HVHDF is producing encouraging clinical observations. Among the findings highlighted by the company are improvements in treatment experience and evidence that patients may experience fewer common dialysis-related symptoms.
Charles Hugh-Jones, MD, FRCP, Global Chief Medical Officer at Fresenius Medical Care, said early data indicate that a significant proportion of patients receiving treatments with the company’s AutoSub Plus technology are reaching the target convective volume associated with high-volume hemodiafiltration.
More than 70% of treatments using AutoSub Plus technology are currently reaching the HVHDF target of at least 23 liters of convective volume per treatment, according to the company.
Fresenius Medical Care also reported that early patient observations include fewer muscle cramps. The company said available data show a 40% reduction in muscle cramps, a finding that could have implications for treatment tolerability and the overall dialysis experience.
These early observations are still being collected and evaluated. Fresenius Medical Care emphasized that U.S. data collection remains ongoing, meaning the findings represent an emerging evidence base rather than a completed analysis of the initiative.
Nevertheless, the initial U.S. experience is reportedly consistent with findings from a broader international body of evidence examining high-volume hemodiafiltration. That evidence includes randomized clinical studies, observational research and real-world data accumulated over more than two decades.
Building on International Evidence and the CONVINCE Trial
The BEACON-US initiative is being developed against the backdrop of a growing international evidence base for high-volume hemodiafiltration.
HVHDF has already been widely adopted in a number of countries and is used as part of routine dialysis care in many healthcare systems. Evidence from multiple countries has investigated its potential impact on clinical outcomes, treatment tolerability, hospitalization rates and survival.
One of the most significant studies supporting the therapy is the CONVINCE trial, a major European randomized clinical study funded by the European Union. The study compared high-volume hemodiafiltration with conventional high-flux hemodialysis and evaluated outcomes among people receiving maintenance dialysis.
Published in the New England Journal of Medicine, the CONVINCE trial reported a 23% lower risk of death from any cause among participants receiving high-volume hemodiafiltration compared with those receiving conventional high-flux hemodialysis. The study also reported improvements in patient-reported outcomes.
Additional international randomized and real-world research has associated high-volume hemodiafiltration with several potential advantages, including fewer hospitalizations, fewer missed dialysis treatments, improved treatment tolerability and fewer episodes of low blood pressure during dialysis.
For Fresenius Medical Care, BEACON-US provides an opportunity to determine how those observations translate into the U.S. healthcare environment and into everyday clinical practice.
Understanding the Role of HVHDF in U.S. Dialysis Care
While high-volume hemodiafiltration has been used internationally for years, its broader deployment in the United States creates an opportunity to gather evidence specific to American patients, providers and dialysis facilities.
BEACON-US is intended to provide insight into how the therapy performs under routine conditions rather than only within controlled clinical trial settings. Real-world evidence can help clinicians understand how a treatment functions when it is integrated into ordinary workflows, with patients representing a wide range of characteristics and clinical needs.
This distinction is particularly important in dialysis care, where patients may differ considerably in age, underlying disease, cardiovascular status, treatment tolerance and other factors that can affect their experience during dialysis.
By expanding the U.S. evidence base, Fresenius Medical Care expects BEACON-US to help clinicians and healthcare systems evaluate the therapy from both clinical and operational perspectives.
The company said early U.S. observations demonstrate strong clinical performance. Among the reported findings are improved achievement of dialysis adequacy targets, as measured by Kt/V, as well as the ability to achieve higher convective volumes without increasing treatment duration.
Maintaining treatment times while achieving a higher convective volume may be important for dialysis providers and patients because dialysis schedules are already demanding and can affect quality of life, staffing and facility capacity.
Higher Convective Volume Without Longer Treatment Sessions
A central characteristic of HVHDF is its use of convection in addition to diffusion to enhance the removal of substances from the blood.
Conventional hemodialysis primarily relies on diffusion, in which waste products move across a semipermeable membrane from the blood into dialysis fluid based on concentration differences. Hemodiafiltration combines this process with convection, using fluid movement across the dialysis membrane to support removal of a broader range of accumulated substances.
For high-volume hemodiafiltration, the therapy is defined by achieving a convective volume of at least 23 liters per treatment.
Because convective volume can be prescribed and measured, clinicians can track whether the intended therapeutic dose has been delivered. This provides an additional measurable parameter when assessing the implementation of HVHDF in clinical practice.
Fresenius Medical Care said its early U.S. experience suggests that AutoSub Plus technology can help facilities achieve the required convective volume target in a substantial majority of treatments.
The technology is also designed to automate aspects of therapy delivery. According to the company, intelligent automation can simplify clinical workflows and help optimize the use of resources within dialysis facilities.
The company further reported that the technology can contribute to a quieter treatment environment, potentially benefiting both patients and healthcare professionals working in dialysis clinics.
Potential Benefits for Patients and Providers
The potential value of HVHDF extends beyond measures of dialysis adequacy.
Dialysis is a recurring treatment that can place a considerable physical and emotional burden on patients, particularly when therapy is associated with symptoms such as muscle cramps, low blood pressure or fatigue.
Fresenius Medical Care said early observations from the U.S. rollout indicate that some patients are reporting improved experiences during and following dialysis. The reported reduction in muscle cramps is one example cited by the company.
International research has also suggested potential benefits related to hospitalization and survival, although these findings need to be considered in the context of the individual study designs and patient populations involved.
For healthcare providers, operational considerations are equally important. If high-volume HDF can achieve higher convective volumes without extending treatment time, it may be possible to integrate the therapy into existing schedules without requiring additional chair time.
At the same time, automation may reduce some of the complexity associated with delivering the therapy and support more efficient use of staff and equipment.
Fresenius Medical Care believes these factors could become increasingly relevant as dialysis providers face growing patient demand and pressures to balance clinical quality with operational efficiency.
Real-World Evidence to Guide Future Kidney Care
The launch of BEACON-US reflects a growing emphasis on real-world evidence as healthcare companies and providers seek to understand how therapies perform outside traditional clinical trial environments.
Controlled randomized trials remain essential for establishing comparative efficacy and safety, but real-world studies can offer additional information about how treatments are implemented across diverse clinical settings.
For dialysis, this may include differences in patient populations, facility practices, treatment protocols and technology utilization. Gathering data across these circumstances can help clinicians build a more complete understanding of a therapy’s role in routine care.
Fresenius Medical Care said the BEACON-US program will continue generating U.S.-specific information as the rollout of high-volume HDF progresses.
The company is also positioning the initiative within its broader strategy to advance innovation in kidney care. As dialysis technology evolves, evidence generation will be increasingly important in determining which approaches offer meaningful benefits for patients and healthcare systems.
The announcement of BEACON-US marks an important development in Fresenius Medical Care’s U.S. expansion of high-volume hemodiafiltration. The initiative combines ongoing clinical evidence generation with real-world experience to evaluate how HVHDF performs among patients receiving dialysis in everyday U.S. practice.
Early observations from the program indicate that a significant proportion of treatments using AutoSub Plus technology are achieving the 23-liter convective volume target. Fresenius Medical Care has also reported improved achievement of dialysis adequacy targets, higher convective volumes without longer treatment sessions, reduced water consumption and encouraging patient experience findings, including fewer muscle cramps.
These observations complement a substantial international evidence base, including findings from the CONVINCE trial and other randomized and observational studies.
However, U.S. data collection is continuing, and the full significance of the BEACON-US findings will become clearer as additional information is gathered and analyzed.
As kidney disease remains a major and growing healthcare challenge, the development and evaluation of dialysis approaches that may improve outcomes, treatment tolerability and operational efficiency will remain an important priority. Through BEACON-US, Fresenius Medical Care is seeking to provide clinicians, patients and healthcare systems with additional evidence to understand the potential role of high-volume hemodiafiltration in the future of U.S. kidney care.
Source link: https://freseniusmedicalcare.com/
